Company / Working Capital
ENDRA Life Sciences Inc. Working Capital History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$7.2M
FY2020
5-year range
$4.5M / $7.2M
FY2017-FY2020
Trend
+62.0%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $6M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2020 with a 3-year CAGR of +12.8%.
Improved from $6M to $7M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +12.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +12.8%, indicating consistent growth.
- In FY2020, working capital increased 62.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $7.2M | +62.0% |
| FY2019 | $4.5M | -25.3% |
| FY2018 | $6.0M | +18.7% |
| FY2017 | $5.0M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026